Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin by Dusoswa, Sophie A. et al.
Glioblastomas exploit truncated O-linked glycans for
local and distant immune modulation via the
macrophage galactose-type lectin
Sophie A. Dusoswaa,b, Jan Verhoeffa,1, Erik Abelsc,d,1, Santiago P. Méndez-Huergoe, Diego O. Crocie,f, Lisan H. Kuijpera,
Elena de Miguela, Valerie M. C. J. Woutersa, Myron G. Bestb,g, Ernesto Rodrigueza, Lenneke A. M. Cornelissena,
Sandra J. van Vlieta, Pieter Wesselingg, Xandra O. Breakefieldc,d, David P. Noskeb, Thomas Würdingerb,c,d,
Marike L. D. Broekmanc,d,h,i, Gabriel A. Rabinoviche,j,2, Yvette van Kooyka, and Juan J. Garcia-Vallejoa,2
aDepartment of Molecular Cell Biology & Immunology, Amsterdam Infection & Immunity Institute and Cancer Center Amsterdam, Amsterdam UMC, Vrije
Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands; bDepartment of Neurosurgery, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HZ
Amsterdam, The Netherlands; cDepartment of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, Boston, MA
02129; dDepartment of Radiology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, Boston, MA 02129; eLaboratorio de
Inmunopatología, Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, C1428ADN Buenos Aires,
Argentina; fLaboratorio de Inmunopatología, Instituto de Histología y Embriología de Mendoza, Consejo Nacional de Investigaciones Científicas y Técnicas,
Facultad de Ciencias Exactas y Naturales, Universidad Nacional de Cuyo, C5500 Mendoza, Argentina; gDepartment of Pathology, Cancer Center Amsterdam
and Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands; hDepartment of Neurosurgery,
Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; iDepartment of Neurosurgery, Haaglanden Medical Center, 2512 VA The Hague,
The Netherlands; and jDepartamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, C1428EGA Buenos
Aires, Argentina
Contributed by Gabriel A. Rabinovich, December 24, 2019 (sent for review May 8, 2019; reviewed by Ignacio Melero and Celso A. Reis)
Glioblastoma is the most aggressive brain malignancy, for which
immunotherapy has failed to prolong survival. Glioblastoma-
associated immune infiltrates are dominated by tumor-associated
macrophages and microglia (TAMs), which are key mediators of
immune suppression and resistance to immunotherapy. We and
others demonstrated aberrant expression of glycans in different
cancer types. These tumor-associated glycans trigger inhibitory
signaling in TAMs through glycan-binding receptors. We inves-
tigated the glioblastoma glycocalyx as a tumor-intrinsic immune
suppressor. We detected increased expression of both tumor-
associated truncated O-linked glycans and their receptor, macro-
phage galactose-type lectin (MGL), on CD163+ TAMs in glioblastoma
patient-derived tumor tissues. In an immunocompetent orthotopic
glioma mouse model overexpressing truncated O-linked glycans
(MGL ligands), high-dimensional mass cytometry revealed a wide
heterogeneity of infiltrating myeloid cells with increased infil-
tration of PD-L1+ TAMs as well as distant alterations in the bone
marrow (BM). Our results demonstrate that glioblastomas ex-
ploit cell surface O-linked glycans for local and distant immune
modulation.
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Glioblastoma (World Health Organization grade IV [WHOIV] glioma) is the most common and aggressive brain ma-
lignancy, with a median overall survival of less than 15 mo (1),
for which immunotherapy has, to date, failed to achieve major
advances. Sustainable responses remain limited to a number of
individual patients benefiting from early-phase clinical trials (2, 3).
Because some of these patients show impressive results (3, 4), the
future for immunotherapy in glioblastoma is promising, but
the brain is an immunologically challenging environment, and the
complexity of immune suppression in glioblastoma is not yet fully
elucidated.
The surface of mammalian cells is highly glycosylated, and the
composition of this glycan coating depends on the activation
status, environmental stimulation, aging, and malignant trans-
formation of the cell (5, 6). Immune cells express a variety of
glycan-binding receptors (lectins), which could modulate the
immune response through interactions with tumor-associated
glycans (5, 7). Therefore, glycans and their glycan-binding recep-
tors could play a crucial role in glioblastoma immune escape.
Glioblastoma immune infiltrates are dominated by tumor-
associated macrophages (TAMs) and microglia (8, 9), which
contribute to immunotherapy resistance (10). TAMs express
glycan-binding receptors including C-type lectin receptors (CLRs)
and sialic acid-binding Ig-like lectins (siglecs) (6). These re-
ceptors specifically recognize glycan structures, often resulting
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in internalization and immune inhibitory signaling (5, 6, 11, 12).
Several studies have demonstrated the involvement of glycan-
binding receptors such as siglecs, dendritic cell (DC)-specific
ICAM-3-grabbing nonintegrin 1 (DC-SIGN) and macrophage-
galactose lectin (MGL) in immune suppression (6, 13–16). MGL
belongs to the family of CLRs which specifically recognize gly-
cans on pathogens and glycoproteins and trigger phagocytosis
and signaling, thereby contributing to modulation of immune
responses (17). MGL is typically expressed by immature DCs
(18) and alternatively activated macrophages (19), conferring
immune-suppressive (tolerogenic) signaling (20, 21). Binding of
MGL to its ligands contributes to immune suppression by increasing
IL-10 secretion and induction of T cell apoptosis (6, 22, 23).
Glycosylation is one of the major and most complex post-
translational modifications of proteins. The two major groups
of glycans, formed with the aid of a variety of glycosyltransferases
and glycosidases, are N-linked (Asn-linked) and O-linked (Ser/
Thr-linked) glycans. Malignant transformation is accompanied
with differential expression of multiple components of this glyco-
sylation machinery (24, 25). Typical tumor-associated glycans arise
from incomplete glycosylation leading to the formation of trun-
cated glycans, or de novo glycosylation, such as sialylated Lewis
antigens (24). Aberrant protein glycosylation is deeply enrooted in
malignant transformation and contributes to aggressive tumor
behavior due to altered protein function and cell−cell interactions.
Well-known pathological processes that promote tumor progres-
sion via glycosylation include modulation of growth factor ac-
tivity, impaired cell−cell adhesion due to aberrant glycoforms of
E-cadherin promoting tumor cell invasion, and metastasis for-
mation via tumor-associated N-linked glycans (Lewis antigens)
that form the ligands for selectins (15, 24). Recent evidence
demonstrates that cancer-associated glycan changes also contrib-
ute to cancer aggressiveness by triggering antiinflammatory sig-
naling circuits in tumor-infiltrating immune cells (6, 15, 16, 22–
24, 26–28). Tumor-associated glycans that are relevant for im-
mune modulation include sialic acids, (sialylated) Lewis antigens,
galectin ligands, and truncated O-linked glycans, such as the Tn
antigen or its sialylated version (sTn), and we recently have col-
lectively coined them as the cancer “glyco-code” (6).
In this study, we sought to identify glycan-based regulatory
circuits in glioblastoma. We investigated whether the glioblastoma
glyco-code could act as a tumor-intrinsic immune suppressor. First,
we detected increased expression of tumor-associated truncated
O-linked glycans in brain tumor tissues derived from patients with
a glioblastoma compared to those from lower-grade diffuse glio-
mas (LGG) or epilepsy. Next, we evaluated the expression of
MGL, a known immunosuppressive CLR on macrophages and
DCs that interacts with truncated O-linked glycans. Stimulation
of MGL by its ligands resulted in increased tumor infiltration by
immune cells with an immune-suppressive phenotype. By over-
expressing truncated O-linked glycans in a murine model, we
studied the influence of these glioblastoma-associated glycans on
immune composition using high-dimensional characterization
of the tumor infiltrate, splenocytes, and bone marrow (BM) by
mass cytometry.
Results
Glioblastomas Overexpress Tumor-Associated O-Linked Glycans. Using
a broad panel of lectins, we initially profiled several glioblastoma
cell lines (U78, U251, U373, and GBM8) for their glycan com-
position (SI Appendix, Fig. S1) and found reactivity against the
α-GalNAc-specific snail lectin Helix pomatia agglutinin (HPA),
which recognizes, among others, the cancer-associated Tn an-
tigen (29, 30) (Fig. 1 A and B). Tn antigen is neoexpressed or
overexpressed in many types of cancer, including gastrointestinal
cancers, lung cancer, and breast cancer (6, 31). High expression of
Tn antigen has been reported in human glioblastoma cell lines
(32). Although Tn antigen has never been reported in healthy
human brain tissue, syndecan-3−associated Tn antigen has been
described as a transiently expressed antigen during the develop-
ment of the mouse brain (33, 34). To further investigate the po-
tential relevance of Tn antigen in glioma (WHO II to IV) patients,
we assessed the relative expression of 270 genes involved in the
glycosylation machinery (SI Appendix, Table S1) in a publicly
available microarray dataset (Fig. 1C) (35). We observed dif-
ferent messenger RNA expression profiles in control brain tis-
sues, LGG, and glioblastomas, suggesting an association between
gliomagenesis and aberrant regulation of the glycosylation ma-
chinery. Among 42 glycosylation-related genes that were differ-
entially expressed in glioblastomas versus healthy control tissues,
we found 10 genes encoding for glycosyltransferases involved in
the O-linked glycosylation pathway (Fig. 1D), suggesting an al-
teration of O-glycosylation in glioblastomas. Among the genes
involved in the synthesis of the Tn antigen, GALNT1, GALNT2,
GALNT7, and GALNT10 were up-regulated in glioblastoma (Fig.
1D). Altered GALNT expression in glioblastoma has not been
described in the literature, but increased GALNT1, GALNT2, and
GALNT10 have been associated with other malignancies (36–38).
O-linked glycan elongation enzymes C1GalT and GCNT2 were
also increased in glioblastoma versus healthy control brain tissues
(Fig. 1D). In agreement with our observation in the GBM cell lines
(Fig. 1B), the observed reprogramming in the O-glycosylation
machinery could indicate, according to known biosynthetic path-
ways, that the glioblastoma’s glyco-code may be characterized by a
high Tn antigen score. In addition, mucins known to carry the Tn
antigen, such as MUC1 or MUC4, have been previously reported
to be expressed in glioblastoma (39–41). Thus, we hypothesized
that aberrant glycosyltransferase expression in patients with glio-
blastomas points to a glyco-code characterized by the prevalence
of immature O-glycans such as the Tn antigen. To investigate this,
we investigated the presence of HPA-reactive glycans in freshly
collected surgically resected brain tissues from patients. HPA
binding to tumor tissues derived from patients with glioblastoma
confirmed the expression of terminal α-GalNAc−containing
glycans, such as Tn, the most extensively characterized ligand
for MGL (21), in these tumors (Fig. 1E and SI Appendix, Fig.
S2). MGL is a CLR typically expressed by immature DCs and
macrophages conferring immunosuppressive (tolerogenic) sig-
naling (20, 21) via the modulation of IL-10 secretion (6, 22, 23).
To evaluate the expression of MGL ligands (MGL-Ls), we used
our recombinant MGL/mouseFc (42) on immunofluorescence
microscopy (Fig. 1F and SI Appendix, Fig. S2) and used ELISA
on tissue lysates (Fig. 1G). As shown in Fig. 1 F and G, tumor
tissues derived from patients with glioblastoma expressed sig-
nificantly more MGL-Ls compared to resected tissues derived
from patients with epilepsy (P = 0.005) or LGG (P = 0.04). Thus,
glioblastomas overexpress HPA-reactive glycans which are also
ligands of MGL, such as the Tn antigen (6, 24).
TAMs in the Glioblastoma Microenvironment Express More MGL
Compared to Myeloid Cells in Patient-Derived Lower-Grade Glioma
and Epilepsy Tissues. Given the prominent infiltration of suppres-
sive myeloid cells in glioblastomas (9, 43, 44) and the abundance
of MGL-L, we investigated the presence of MGL+ myeloid cells
within the tumors. Patient-derived glioblastoma tissues were
highly infiltrated with MGL+ cells (Fig. 2A and SI Appendix, Fig.
S2) that were also CD163+ (Fig. 2B), a phenotype that is typically
associated with immune-suppressive TAMs. In silico analysis of a
publicly available dataset (35) also showed higher expression of
MGL (Fig. 2C, P = 0.017) and CD163 (Fig. 2D, P = 0.0002) in
glioblastoma, as well as a significant moderate correlation be-
tween the two (Fig. 2E, R = 0.29, P < 0.0001). This finding further
supports our discovery that MGL is expressed by immune-
suppressive CD163+ macrophages, but also by other cells in the
glioblastoma microenvironment. The Cancer Genome Atlas data
show a survival benefit for patients with lower expression levels of






















MGL (Fig. 2F, P = 0.032), further supporting our hypothesis that
triggering of the MGL/MGL-L axis could represent a mechanism
by which the tumor glycocalyx contributes to immune suppression
in the glioblastoma microenvironment.
High-Dimensional Characterization of the Immune System in a Murine
Glioma Model. In order to recapitulate in vivo the MGL-LHi phe-
notype observed in human glioblastoma tissues, we knocked out
the C1galt1c1 gene (also known as Cosmc) in the mouse glioma
cell line GL261 using CRISPR/Cas9. Cosmc is a chaperone nec-
essary for the synthesis of T antigen using the Tn antigen as sub-
strate (Fig. 1A). Loss of Cosmc activity results in abrogation of
extended Core 1 and Core 2 O-linked glycans and accumulation of
(s)Tn-rich glycoproteins on the surface of the Cosmc−/− cells (45).
Indeed, GL261 lacking Cosmc expression appeared to have a TnHi
(SI Appendix, Fig. S3A), MGL-LHi (SI Appendix, Fig. S3 B and C)
phenotype, even in established tumors 14 d after intracranial in-
jection. To study whether the overexpression of MGL-Ls on
glioblastoma cells triggered a tolerogenic phenotype on macro-
phages, we tested, in vitro, the impact on the expression of PD-L1,
CD206, CD200R, and CCR2. The results, both on macrophages
and microglia, clearly demonstrated that the glioma MGL-LHi
cells induced higher expression of tolerogenic markers on mac-
rophages and expression of IL-10 on microglia (SI Appendix, Fig.
S4). In order to address the effects of MGL-L expression on the
local intratumor and peripheral immune system, we performed
high-dimensional analysis using cytometry by time-of-flight mass
spectrometry (CyTOF) (46). We characterized tumor infiltrates
Fig. 1. Glioblastomas overexpress immature O-linked glycans. (A) Schematic representation of the O-glycosylation pathway. More than 20 different GALNTs
have been characterized in humans that have overlapping activity but differ in peptide substrate specificities and expression pattern. GalNAc transferases
catalyze the synthesis of GalNAcα1-O-serine/threonine (also known as the Tn antigen) as the first step in O-glycosylation (38). The Tn antigen is further
elongated by the concerted action of several glycosyltransferases. (B) HPA binding to four glioblastoma cell lines (U87, U251, U373, and GBM8) measured by
flow cytometry. (C) Heatmap of publicly available microarray data showing expression of genes encoding for glycosyltransferases and glycosidases in healthy
brain tissue samples and 240 glioma WHO II (astrocytomas and oligodendrogliomas, n = 21), WHO III (astrocytomas and oligodendrogliomas, n = 60), and
WHO IV (n = 159) samples. (D) Volcano plot showing 270 glycosylation-specific genes (SI Appendix, Table S1) with O-linked glycosylation related genes
highlighted. C and D include a reanalysis of raw data obtained from Gravendeel et al. (35), including, for D, healthy brain tissue (n = 8), astrocytoma WHO II
(n = 13), astrocytoma WHO III (n = 60), and glioblastoma (WHO IV, n = 159) samples. (E) Seven-micrometer cryosections of surgical epilepsy, LGG, and
glioblastoma (GBM) samples, representative for five patients per condition, stained with HPA (green) and Hoechst as nuclear counterstain (blue). (F) Seven-
micrometer cryosections of surgical epilepsy, LGG, and glioblastoma samples, representative for five patients per condition, stained with MGL-mouseFc (red)
and Hoechst as nuclear counterstain (blue). (G) Human MGL-binding ELISA with lysates of glioblastoma (n = 12), LGG (n = 5), and epilepsy (n = 8) tissues,
showing a significant difference (*P < 0.01, ***P = 0.005) between glioblastoma, and epilepsy samples (OD 450 nm).










































(brain) and systemic (BM and spleen) immune composition,
comparing mice with established GL261-MGL-LHi tumors to
GL261-wild-type (WT) tumors 14 d after orthotopic implanta-
tion. Our antibody panel included 37 metal-conjugated anti-
bodies (SI Appendix, Table S2) and enabled the identification of
immune cell lineages, complemented with functional markers for
subclassification. Our workflow (SI Appendix, Fig. S5) was based
on clustering and visualization using Hierarchical Stochastic
Neighbor Embedding (HSNE), a derivation of t-distributed
(t)SNE in which hierarchies of nonlinear similarities are built that
can be interactively explored in a stepwise manner (47) within the
Cytosplore (48) environment. First, all cells from the brains, BM,
and spleens of 20 mice (10 mice with GL261-MGL-LHi tumors
and 10 mice with GL261-WT tumors) were classified into main
cell clusters at the overview level according to similarity in the
multidimensional space. HSNE built a hierarchical representa-
tion of the complete dataset (∼12 × 106 cells), without down-
sampling, and allowed for subsequent clustering of the cells into
consecutive levels. Across the different tissue samples, we iden-
tified 12 major overview-level cell clusters (A through L) with
distinct phenotypes. Based on their relative marker expression,
color-coded onto the HSNE maps, clusters from the lymphoid and
myeloid cell lineages located to different areas of the HSNE map
(Fig. 3 A–C and SI Appendix, Fig. S6). T lymphocytes localized
together in cluster E (CD45+CD3+), whereas myeloid populations
were spread over clusters A, F, and G (CD45+CD11b+Ly6C+).
Clusters A and G also expressed the granulocyte marker Gr-1.
Ki67+ proliferating cells were mainly located in cluster K and
part of F. Clusters D, J, K, and L represented four types of
CD45−CD11b−CD3−Gr1− nonimmune cells, and, due to the
expression of Ki67 (Fig. 3A) and GFP (SI Appendix, Fig. S6) in
cluster K and their essentially exclusive localization in the brain
(Fig. 3 D and E), these cells were identified as GFP+ GL261
tumor cells. Cells derived from the tumor-bearing brain located
predominantly in clusters F (myeloid), K (tumor), and L (CD45−;
Fig. 3 D and E). Therefore, cluster F represented a large group
of CD45+CD11b+ myeloid cells in the brain. Compared to this
large number of tumor-infiltrating myeloid cells, tumor-infiltrating
T lymphocytes (CD45+CD3+TCRβ+, cluster E) were largely
underrepresented, which corresponds to recent literature de-
scribing poor lymphocyte infiltration of glioblastomas (2, 49).
Clusters E (T lymphocytes), G (Gr1+), H (CD45+, lineage−), I
(CD45+CD11c+), and J (CD45−) were mostly represented in the
spleen (Fig. 3 D and E), where cluster I was positive for the DC
marker CD11c. The BM was mainly populated by cells that were
assigned to clusters A (CD45+CD11b+ myeloid cells), B (CD45+,
lineage−), I, C (CD45+Ly6C+), and D (CD45−). HSNE maps
color-coded for all markers are provided in SI Appendix, Fig. S6.
Since cluster A represented the most dominant cluster of mye-
loid cells in the BM, E represented T lymphocytes which could be
differentially activated in the context of glioma glycoforms, and F
represented the dominant cluster of (myeloid) immune cells in
the brain, we choose to compare these clusters between mice
with GL261-MGL-LHi tumors and mice with GL261-WT tumors
in subsequent analyses.
Glioblastoma-Associated MGL-Ls Attract PD-L1+ TAMs. Since cells
from the myeloid lineage formed the largest group of immune
cells infiltrating the tumor-implanted mouse brains, we explored
the phenotypes of brain-derived myeloid cells before we com-
pared them between the two study groups. We zoomed into the
HSNE embedding of cluster F (brain myeloid, Fig. 4A) and
identified 16 distinct subclusters (Fig. 4B). The cell density (Fig.
4C), mouse sample identity (ID, showing absence of sample bias;
Fig. 4D), and the expression levels of myeloid markers (CD45,
CD11b, Ly6C, Gr1, and CD11c) were overlaid on the HSNE
map (Fig. 4E). The phenotypes of the 16 subclusters of brain-
infiltrating myeloid cells were characterized by lineage myeloid
markers, activation markers such as Sca-1 and PD-1, and mi-
gration markers such as CCR2 (Fig. 4 F and G). The size of the
clusters (percentage of live cells in the brain samples) was
quantified in the bar graph lining the right side of the heatmap in
Fig. 4G. Given the combined expression of CD45, CD11b, Ly6C,
and CCR2 on most of the subsets (F1, F3, F5, F9, F12, F13, F14,
and F15), these tumors were likely highly infiltrated with monocyte-
derived macrophages in different stages of differentiation (44).
Fig. 3. High-dimensional mass cytometric analysis of a murine model for
glioblastoma overexpressing immature O-linked glycans. (A) Overview
level HSNE clustering of 12-mln cells pooled from brains, BM, and spleens
of the 20 mice (10 MGL-LHI and 10 WT tumors), showing cell density within
different clusters, and expression of some key markers for cell lineage
identification. (B) HSNE map, color-coded by cluster as identified in the
first-level HSNE clustering. (C ) Summary of cluster phenotypes. (D) HSNE
maps selectively showing cells originating from brain, spleen, or BM. (E )
Percentages of cells per cluster, relative to the total number of cells per
organ (brain, spleen, or BM).
Fig. 2. TAMs in the glioblastoma microenvironment express MGL. (A) Human
glioblastoma, LGG, and epilepsy tissues, representative for five patients per
condition, stained for the MGL receptor (yellow) and nuclei (blue). (B) Human
glioblastoma tissue stained for the MGL receptor (yellow), CD163 (red), and
nuclei (blue). (C) MGL expression in glioblastoma, astrocytoma grades II and III,
and control tissues. (D) CD163 expression in glioblastoma, astrocytoma grades II
and III, and control tissues. (E) Scatterplot with expression of CD163 on the x
axis and MGL on the y axis showing a moderate correlation in glioblastoma
tissue (Pearson’s R = 0.29, P ≤ 0.0001). C−E include a reanalysis of raw data
obtained from Gravendeel et al. (35), including, for C and D, healthy brain
tissue (n = 8), astrocytoma WHO II (n = 13), astrocytoma WHO III (n = 60), and
glioblastoma (WHO IV, n = 159) samples. (F) Kaplan−Meier curve showing
survival benefit for patients with lower expression of MGL (n = 84) versus
patients with higher expression of MGL (n = 85, P = 0.032, with median ex-
pression value of 3.25 as cutoff). *P < 0.05, **P < 0.01, ***P < 0.001.






















Fig. 4. Glioblastoma-associatedMGL-Ls attract CCR2+PD-L1+ macrophages. (A) HSNE map with the main clusters of interest highlighted. (B) HSNE map, colored by
16 subclusters as identified in the second-level HSNE subclustering of cluster F: tumor-infiltrating myeloid cells. (C) Density features depicting the local probability
density of cells in cluster F. (D) Sample distribution. Each color represents a mouse, indicating a lack of sample bias in our data. (E) HSNE maps representing relative
expression of the classifying myeloid markers (CD45, CD11b, Ly6C, Gr1, and CD11c). (F) HSNE maps representing relative expression of functional markers (Sca-1,
CCR2, PDL-1, and PD-1). (G) Heatmap with relative ArcSinH(5) transformed expression of shownmarkers in the second-level HSNE of cluster F (Left) with a bar graph
showing the percentages of total live cells in the brain per cluster (Right). (H) The three subclusters (F5, F7, and F16) with statistically significant differences in size
between MGL-LHi and WT tumors. (I) Networks of subclusters from WT (Left) and MGL-LHi (Right) tumors with nodes visualizing all of the level-two cell subclusters
in the experiment and edges representing correlation coefficients for relationships between subclusters. The size of the nodes represents the size of the population,
the color intensity of the nodes represents the number of connections to other nodes, and the color intensity of the edges represents the correlation coefficient.
The orange nodes highlight population F16, and the red nodes highlight the nearest neighbors of population F16 in both MGL-LHi- and WT tumors. ***P < 0.001.










































Some of the immature macrophage subclusters could also be
classified as monocytic myeloid-derived suppressor cells (MDSC)
based on their expression of CD11b, Gr-1, and Ly6C (F1, F5, F9,
and F12) (50). Clusters F14 and F15 could also be monocyte-
derived DCs due to the expression of CD11c. Low expression
levels of Ly6C in some of the other CD45hiCD11b+ subsets may
indicate a more mature differentiated type of macrophages (sub-
clusters F2, F6, F7, F8, and F16) or DCs (F4), although most of
these subclusters still expressed high levels of CCR2 (subclusters
F4, F6, F7, and F16). This could contribute to retention of the cells
in the CCL2+ tumor microenvironment (51, 52). The phenotypes
of subclusters that are CD11b+CD45dimCD49d− such as F10 and
F11 correspond mostly to the classical definition of microglia.
These cells were clearly outnumbered by the high number of im-
mature and mature CD45hi myeloid cells. Microglia-like subcluster
F10 displayed activation and proliferation markers, given the ex-
pression of Ki-67, Sca-1, CCR2, and CD54. Also, clusters F5 and
F8 showed relatively low expression of CD45 and hierarchically
clustered close to F10 and F11, implying a possible microglia-like
phenotype. Looking more into the expression profile of other
markers, F5 is Ly6C+ and F8 is CD11c+, which could be signs of
activation or plasticity. The brain-derived myeloid subclusters were
mostly positive for activation markers Sca-1 and CD54. In
summary, the immune infiltrate in the GL261 (both WT and
MGL-LHI)-harboring mouse brains was dominated by cells
from the myeloid lineage with a wide heterogeneity of phe-
notypes that corresponded to classical definitions of microglia,
monocyte-derived macrophages, and MDSC, but also show
variations to the classically described phenotypes. We next
explored the frequency (percent live cells) of myeloid sub-
clusters as percentage of total live brain-derived cells and dis-
covered three subclusters that were significantly larger in the
MGL-LHi tumors (Fig. 4H): subcluster F5, F7, and F16. All
three clusters were positive for CD45, CD11b, CXCR5, and
Sca-1, but showed slightly different phenotypes: F5 was Ly6C+;
subcluster F7 was CD49d+CCR2+CD54+PD1+PD-L1+, and the
largest subcluster (F16) was CD16/32+CCR2+CD54+PD1+PD-L1+.
Frequencies of all of the clusters with significant differences in
any of the organs are summarized in SI Appendix, Fig. S7. Since
the immune system shows features of a complex network (53, 54),
we further looked into the size of all of the HSNE subclusters
spread over brain, spleen, and BM, and generated a robust cor-
relation matrix for cluster sizes in MGL-LHi tumors and WT
tumors (Fig. 4I). Statistically significant correlations were visu-
alized in a correlation network with edges (lines) indicating a
correlation between two subclusters, and nodes representing the
subclusters coded by size for mean subcluster size and coded by
color for the number of correlations (edges) with other sub-
clusters. Subcluster F16 turned out to be particularly interesting,
not only because it was the largest subcluster of myeloid cells
with a significant increase of 7% of live cells in the brains with
WT tumors to 12% of live cells in the brains with MGL-LHi tu-
mors (Fig. 4H) but also because of the gain of systemic corre-
lations in the MGL-LHi tumors, especially with subcluster A1
(CD45+CD11b+Ly6C+Gr1+CCR2+). In the networks, F16 is
shown as the orange cluster, with its nearest neighbors in red
(Fig. 4I). Thus, in MGL-LHi tumors, increased numbers of
myeloid cells accumulated, especially from subcluster F16,
which represents a phenotype that corresponds to the de-
scription of PD-L1+ monocyte-derived macrophages (9, 44, 52,
55, 56). In mice with MGL-LHI tumors, this population (F16)
gained a strong correlation with subcluster A1 in the BM as
well as some smaller BM clusters. An equivalent of these cells
characterized by the expression of CD163, PD-L1, and CCR2
can also be found in tissue derived from glioblastoma patients
(SI Appendix, Fig. S8).
Glioblastoma-Associated MGL-Ls Affect the Myeloid Composition of
the BM. From the correlation networks in Fig. 4I, BM subcluster
A1 (CD45+CD11b+Ly6C+Gr1+CCR2+) stands out as a large
subcluster with a significant correlation with the brain tumor
macrophage subcluster F16. Therefore, we selected HSNE
overview-level cluster A to look in further detail into the subclus-
ters of myeloid cells in the BM.We embedded cluster A at the next
HSNE level (Fig. 5 A and B), and visualized cell density (Fig. 5C),
mouse ID (Fig. 5D), and the expression levels of classifying myeloid
markers overlaid on the HSNE maps (Fig. 5E). The second HSNE
level of cluster A resulted in 16 BM myeloid subclusters (Fig. 5
F and G). Subclusters A2 (CD45+CD11b+Ly6C+Gr1+Sca-1+),
A5 (CD45+CD11b+Ly6C+Siglec-H+CXCR5+CCR2hi), and A12
(CD45+CD11b+Ly6C+Gr1+Sca-1+CCR2+) were significantly de-
creased in the BM of mice with MGL-LHi tumors (Fig. 4H), which
could result from either a decline in BM production of these cells
or an increased recruitment to the tumor. Subclusters A1 and A4
(CD45+CD11b+Ly6C+Gr1+) showed a significant increase in size
in the BM of mice implanted with MGL-LHi tumors, possibly
caused by tumor-induced increased production (Fig. 5H). Cross-
talk of glioblastoma cells with BM-derived MDSCs has been de-
scribed (8) and could be regulated by soluble proteins, and pos-
sibly also via extracellular vesicles and blood platelets (9). In the
network visualization of our correlation analysis, the nearest
neighbors of population A1 (shown in orange with nearest
neighbors in red), indeed lacked correlations between subcluster
A1 in BM and subclusters in the brains in WT tumors, whereas
significant correlations were present in the MGL-LHi tumors (Fig.
5I). So, the altered GL261 glycocalyx influenced not only the
myeloid composition of the local tumor infiltrate but also the
immune cell composition of the BM.
Discussion
In the present study, we evaluated the glioblastoma glyco-code
as tumor-intrinsic modulator of immune suppression. We found
that an α-GalNAc−terminal glycan, possibly the Tn antigen, is
highly expressed on glioblastoma cell lines and in patient-derived
glioblastoma tissues, as well as at lower levels in lower grade
gliomas. In concert, we detected a high infiltration of immune-
suppressive CD163+ TAMs expressingMGL, an immune-suppressive
receptor that binds Tn antigen. In an in vivo murine model re-
capitulating high expression of Tn antigen (MGL-L) on glio-
blastomas, we profiled infiltrating immune cells with a wide
heterogeneity of phenotypes that corresponded to classical def-
initions of microglia and monocyte-derived macrophages, but
also showed variable expression of activation and migration
markers. Our data demonstrate that overexpression of O-linked
glycans increases the frequency of immune-suppressive PD-L1+
macrophages in murine MGL-Lhi tumors as well as inducing
distant alterations in immune cell frequencies in the BM.
O-linked glycosylation is initiated at the Golgi apparatus by a
family of N-acetylgalactosaminyltransferases, which mediate the
addition of N-acetylgalactosamine (GalNAc) to the amino acids
serine or threonine (38). The initial addition of GalNAc to serine
or threonine forms the Tn antigen, which can then be further
extended to form elongated O-linked glycans (38). T synthase is
the key enzyme in the first step of O-glycan elongation, and its
function depends on the chaperone Cosmc (C1GalT1C1) (38,
45). In healthy tissues, Tn antigen is covered by other carbohy-
drates, due to O-linked glycan elongation, but, due to incomplete
glycosylation, it becomes exposed in cancer tissues. After Tn
antigen was first described in breast cancer (57), other studies on
the expression of Tn antigen in cancer followed (6, 14, 24, 31,
58–62). Tn antigen has been reported as a prognostic factor in
lung cancer (63), breast cancer (64), and colorectal cancer (14, 65).
The expression of Tn antigen has been described in human
glioblastoma cell lines (32) and the developing mouse brain (33,
34), but not in healthy human brain tissues. Here, we report






















Fig. 5. Glioblastoma-associated MGL-Ls affect the myeloid composition of the BM. (A) HSNE map with the main clusters of interest highlighted. (B) HSNE
map, colored by cluster as identified in the second-level HSNE clustering of cluster A: BM-derived myeloid cells. (C) Cell density. (D) Sample distribution. (E)
HSNE maps representing relative expression of the classifying myeloid markers. (F) HSNE maps representing relative expression of functional markers. (G)
Heatmap with relative Arcsinh transformed expression of shown markers in the second-level HSNE of population A (Left) with a bar graph showing the
percentages of total live cells in the BM that the subclusters contain (Right). (H) The five subpopulations with statistically significant differences in relative
frequency between mock transfected tumors and Cosmc KO tumors. (I) Networks of subclusters from WT (Left) and MGL-LHi (Right) tumors with nodes
representing all of the subclusters in the experiment and edges representing correlation coefficients for relationships between the subclusters. The size of the
nodes represents the size of the population, the color intensity of the nodes represents the degree (number of connections to other nodes), and the color
intensity of the edges represents the correlation coefficient. The orange nodes highlight population A1, and the red nodes highlight the nearest neighbors of
population A1 in both WT and Cosmc KO tumors. ***P < 0.001.










































overexpression of Tn antigen in glioblastomas compared to
control epilepsy tissues. In microarray data on bulk glioblas-
toma and lower-grade glioma tissues, we detected differential
regulation of O-glycosylation−related genes. Future studies
should be conducted to investigate the proteins expressing Tn
antigen and evaluate the prognostic value of Tn antigen in
glioblastoma. We hypothesized that the expression of Tn an-
tigen could play a role in modulating the immune response via
MGL on macrophages.
Glioblastoma cells exploit many strategies, such as recruitment
of TAMs, to evade the immune system. TAMs comprise at least
one-third of the cells in the glioblastoma microenvironment and
facilitate tumor progression by creating a supportive stroma for
tumor cell proliferation and migration (44). TAMs differentiate
into a phenotype characterized by impaired phagocytic function
and the expression of immunosuppressive cytokines and immune
checkpoint ligands, such as PD-L1, correlated with prognosis
(66, 67). Here we show that human glioblastoma-infiltrating TAMs
express high levels of MGL, a CLR with immune suppressive
properties.
Recapitulating the glyco-code that we identified in human
glioblastomas, we developed a murine model overexpressing the
truncated O-linked glycan Tn antigen. We created a mouse glio-
blastoma cell line (GL261) with increased exposure of Tn antigen
by knocking out the essential chaperone for O-linked glycan
elongation Cosmc (68). The resulting cell line was able to trigger
an M2-like phenotype on macrophages and microglia in vitro.
Using high-dimensional characterization of the tumor infiltrate,
splenocytes, and BM by mass cytometry, we demonstrate a wide
heterogeneity of tumor-infiltrating myeloid cells with increased
infiltration of PD-L1+ TAMs in the MGL-LHI tumors, as well as
alterations of immune cell frequencies in the BM. In the spleens,
we did not find significant or biologically relevant differences.
Future research should focus on the expected role of MGL in this
glycan-dependent mechanism of immune modulation. Although
humans have one type of MGL, mice have two different MGL
genes: mgl1 and mgl2 (69). Based on the glycan specificity, the
mouse homolog of human MGL is MGL2 (70). A diphtheria
toxin receptor knockin mouse targeting the Mgl2 gene is com-
mercially available, but, given the high expression of MGL and
the pronounced role of macrophages in glioblastoma, ideally,
loss of MGL should be studied while maintaining the TAMs.
Future experimental evaluation of mgl2−/− mice (69, 70) should be
performed to further assess the role of truncated O-linked glycan
in immune modulation.
Glioblastoma is an incurable tumor deeply invading the pa-
renchyma of the brain. Glioblastoma cells prefer to travel through
the brain via the subarachnoid space and existing highways such
as white matter tracts (71) or blood vessels (72) with oxygen and
nutrient supply. Presentation of Tn antigen along blood vessels
to infiltrating alternatively activated MGL+ macrophages could
contribute to the immune-suppressive tumor microenvironment
by activating regulatory pathways (22). In the time of precision
medicine, particularly important for immunotherapy, the selec-
tion of glioblastoma patients is challenging. The increased in-
filtration of MGL-LHI glioblastomas by PD-L1+ TAMs could
have implications for patient selection for immune checkpoint
blockade against PD1 or PD-L1. Therefore, future evaluation of
the clinical correlation between Tn antigen expression and PD-L1
expression in glioblastomas would be valuable. Given the high
abundance of MGL ligands in glioblastomas, it would be inter-
esting to explore whether Tn-specific CAR-T cells could be used
in conjunction with anti−PD-L1 therapy for a more effective
immunotherapy. Finally, the interaction between MGL and its
ligands is susceptible to competitive inhibition using the nontoxic
carbohydrate α-GalNAc, a strategy that could be used in combi-
nation with the current gold standard and/or the abovementioned
proposed immunotherapy regime.
Altogether, we conclude that the Tn antigen-dominated
glyco-code in glioblastomas has major consequences for both
local and systemic immune responses, providing possible diagnostic/
therapeutic avenues. We hypothesize that Tn antigen is of prog-
nostic value in glioblastoma, as it is in several other types of cancer,
and that this glycan may modulate the anti-glioblastoma immune
response both locally and systemically. Follow-up studies should
focus on the prognostic potential of Tn antigen and its potential
for selection of patients for immune checkpoint inhibition, and
investigate patient blood signatures to evaluate systemic immune
modulation.
Materials and Methods
Cell Culture. Human glioblastoma U87, U251, U373, and GBM8 cell lines and
mouse GL261 cell lines (Developmental Therapeutics Program/National Cancer
Institute Tumor Repository, Charles River Laboratories, Inc.) were cultured un-
der standard conditions with 5% CO2 and 37 °C in a humidified incubator. U87,
U251, and U373 cells were maintained in Dulbecco’s Modified Eagle Medium
(Thermo Fisher) supplemented with 100 U/mL penicillin/streptomycin
(Lonza), 2 mM L-glutamine (Lonza), and 10% fetal calf serum (FCS) (Biowest).
GBM8 cells were maintained in Neurobasal medium (Invitrogen) supple-
mented with 100 U/mL penicillin/streptomycin (Lonza), 2 mM L-glutamine
(Lonza), 1× B27 supplement (Life technologies), 0.5× N2 supplement (Life
Technologies), 20 nM recombinant human fibroblast growth factor (Pepro
Tech), 20 nM recombinant human epidermal growth factor (Pepro Tech),
and 20 μg/mL heparin (Sigma). Mouse glioma GL261 cells grow in Roswell
Park Memorial Institute medium (RPMI; Thermo Fisher) supplemented with
100 U/mL penicillin/streptomycin (Lonza), 2 mM L-glutamine (Lonza), and
10% FCS (Biowest). To introduce reporter molecules, the mouse glioma
Gl261 cell line was stably transduced using a CSCW2 lentiviral vector (73)
encoding for firefly luciferase and GFP separated by an internal ribosome
entry site (IRES) domain (GL261.Fluc.IRES.GFP).
Generation of GL261-MGL-LHi Cells. GL261.Fluc-IRES.GFP cells were transfected
with a CRISPR/Cas9 construct targeting Cosmc (C1GalT1C1) to generate the
MGL-LHi phenotype or an empty CRISPR/Cas9 construct to generate the GL261-
WT (Mock) phenotype. The CRISPR/Cas9 construct was constituted according to
the protocol as described by Ran et al. (74) using the pSpCas9(BB)-2A-Puro
plasmid (a gift from Feng Zhang, Broad Institute of Massachusetts Institute
of Technology, Addgene #62988). Cosmc (C1GalT1C1) was targeted by the
following guide RNA strands: top CACCGGTTTTCTTACCTCCAAA; bottom
CCAAAAGAATGGAGGTTTCAAA.
Lipofectamine LTX with PLUS reagent (ThermoFisher Scientific) was used for
transfection and applied according to manufacturer’s protocol. One day after
transfection, puromycin was added for selection. Mutated cells were sorted
based on a Tn antigen high phenotype using the Tn antigen-specific snail
lectin HPA (Sigma). Cells were incubated with biotinylated HPA (5 μg/mL;
Vector Laboratories) for 30 min at 4 °C and, after a washing step, incubated
with Streptavidin-AF647 (Jackson Immunolaboratories) for 30 min at 4 °C
before they were sorted on a FACSAria Fusion (BD). Cells were sorted two
times and frozen in aliquots in order to implant low passage cells
into mice.
Surgical Samples. Surgical samples of patients with epilepsy, LGG (Astrocy-
toma WHO II and III), glioblastoma, and intracranial metastasis were collected
and frozen en block or in optimal temperature cutting (OCT)-Compound
(Tissue Tek). All samples were collected at the Amsterdam UMC, location
VU University Medical Center (Amsterdam, The Netherlands) after approval
by The Medical Ethics Review Committee of the Amsterdam UMC and written
informed consent. All patients were diagnosed by clinical presentation at the
Department of Neurology and confirmed by histopathological analysis at the
Department of Pathology of our hospital. Patients with epilepsy underwent
surgery when resistant to medical treatments; patients with LGG and glio-
blastoma underwent surgery as primary treatment followed by radiother-
apy and/or chemotherapy according to treatment standards. Patient samples
were grouped according to the diagnoses assigned by a pathologist in the
Amsterdam UMC, location VU University Medical Center, and handled
according to national and institutional medical ethical standards regarding
the use of human tissue. All patient samples were pseudoanonymized prior to
data analysis.
Syngeneic Mouse Model. Mouse studies were approved by the Massachusetts
General Hospital Institutional Animal Care and Use Committee and performed






















according to their safety and animal well-being guidelines. Mice were main-
tained under a 12-h light/dark cycle with access to water and food. Adult (10 to
12 wk old), male C57/BL/6 mice (Charles River Laboratories) were maintained
under specific-pathogen-free conditions. After anesthetizing mice with iso-
fluorane, 2 μL containing 1 × 105 Gl261.FG-Cosmc-KO or Gl261.FG-Mock cells
were injected into the left striatum (from Bregma: 2 mm anterior, 0.5 mm left,
2.5 mm deep) using a stereotactic frame. After 2 wk, tumor growth was
comparable between groups, and mice were deeply anesthetized with a
mixture of ketamine (17.5 mg/mL) and xylazine (2.5 mg/mL) followed by
transcardial perfusion with 50 mL of Dulbecco’s phosphate-buffered saline
(PBS) without Mg2+ and Ca2+ (DPBS) using a perfusion pump (Minipump
Variable Flow; Fisher Scientific). The brain was then removed and frozen in
OCT-Compound (Tissue Tek) for immunofluorescence, and prepared for mass
cytometry staining or fluorescence-activated cell sorting (FACS).
In Vitro Coculture Assays. Peritoneal macrophages were obtained by peri-
toneal lavage of C57BL/6 mice with 8 mL of PBS supplemented with 10 mM
(ethylenedinitrilo)tetraacetic acid (EDTA). Cells were plated on 24-well plates
and allowed to adhere for 24 h. Upon resting, cells were exposed to Gl261.FG-
Mock or Gl261.FG-Cosmc-KO (ratio 1:5, macrophage:Gl261) for ∼48 h, stained
for CD11b, CD206, CD200R, PD-L1, CD86, CD80, MHC-II, CCR2, CD163, and
CD11b, and measured by flow cytometry. Alternatively, the microglia cell
line BV-2 was used in an identical setting, and the expression of PD-L1 was
measured by flow cytometry or the secretion of IL-10 was determined by
ELISA. Where indicated, the incubation included 500 nM of the MGL in-
hibitor αGalNAc (Sigma).
Lectin Binding (FACS). Glioblastoma cell lines were plated in V-bottom 96-well
plates at a density of 50 to 200 × 103 cells per well and washed with Hank’s
Balanced Salt Solution (HBSS; Gibco) supplemented with 0.5% bovine serum
albumin (BSA). After blocking with HBSS 0,5% BSA (HBA) for 30 min at 4 °C,
cells were incubated with biotinylated HPA (Vector Laboratories) or soluble
recombinant humanMGL-Fc, fused to a human IgG1 fragment, in the absence
or presence of the calcium chelator ethylene glycol bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid. HPA and MGL-Fc binding to glioblastoma cells was
detected using Streptavidin-AF488/AF647 (Jackson Immunolaboratories) or
goat-anti-human-IgG- fluorescein isothiocyanate (FITC)/allophycocyanin (APC)
(Jackson). After 10 min of incubation in 7AAD/eFluor780/eFluor510 (1:1,000;
Jackson Immunolaboratories) in HBA for exclusion of dead cells, fluorescence
signal was measured by flow cytometry (BD Fortessa).
MGL-Binding ELISA. Surgical samples were gently homogenized and incubated
in lysis buffer (5 mM EDTA, 1% Nonidet P-40, 0,5% sodium deoxycholate,
0.1% sodium dodecyl sulfate, 0.15 M NaCl, 50 mM Tris·HCl, 50 mM Tris)
supplemented with protease inhibitors at 4 °C under rotation for 1 to 2 d,
depending on the sample volume. The lysates were centrifuged at 10,000 × g
for 15 min and stored at −80 °C. Protein concentrations were determined by
bicinchoninic acid (BCA) assay (Micro BCA Protein Assay Kit, Thermo Fischer)
with BSA as standard, and diluted until equal protein concentrations were
reached for all samples. Epilepsy and tumor lysates were coated (50 μg/mL)
onto Nunc maxisorb 96-well plates (Nunc) in ELISA coating buffer (0,2 mM Tris·
HCl, pH 9,2) overnight at room temperature (RT). Then 1% BSA in coating
buffer was coated as negative control. Plates were washed in Tris-sodium-
magnesium (TSM) buffer (20 mM Tris·HCl, 150 mM NaCl, 1 mM CaCl2, 1 mM
MgCl2, pH 8.0) and blocked for 30 min at 37 °C with TSM buffer supple-
mented with 1% BSA. Next, recombinant human MGL-Fc, the MGL carbo-
hydrate recognition domain fused to a mouse IgG1 fragment, was added
and incubated for 2 h at RT, mildly shaking, followed by detection by 30 min
of incubation at RT with peroxidase-conjugated goat-anti-mouse-IgG
(Jackson). The reaction was started using a substrate buffer containing
0,1 M Sodium Acetate (Sigma), 0.1 M citric acid (Sigma), pH 4, 0.006% H2O2,
and 0.1 mg/mL tetramethylbenzidine (Sigma) and stopped with a stop
buffer containing 0.2 M H2SO4. Signal was measured using a microplate
absorbance spectrophotometer at a wavelength of 450 nm (Bio-Rad).
Immunofluorescence Microscopy Imaging. Cryosections (7 to 20 μm) of Tissue-
Tek embedded surgical samples or mouse brains were fixed in 2% para-
formaldehyde for 10 min, followed by blocking with either 0.5% BSA in TSM
buffer or HBSS (Gibco) for lectin staining, or 10% serum (species of secondary
antibody) in PBS for antibody staining. Tissue sections were incubated with
primary lectins or antibodies, which were diluted in 1% BSA in TSM or PBS,
respectively, for 2 h at 37 °C or overnight at 4 °C. Antibody binding was de-
tected with fluorochrome-conjugated secondary antibodies, and incubated
for 60 min at RT followed by thorough washing with TSM or PBS. Sections
were counterstained with Hoechst or TO-PRO3 and imaged on a wide-field
fluorescence microscope (Leica DM6000 or Nikon eclipse TE2000-U). Alterna-
tively, fluorescence images were acquired at either 0.5 or 0.25 μm per pixel
resolution, using a Vectra Polaris scanner (Akoya Biosciences) with DAPI, FITC,
TexRed and CY5 filters. Immunopositive cells were identified by DAPI nuclear
staining by applying constant thresholds for light intensity and object size
maintained across all sections with ImageJ software (NIH).
Mouse Brain Single-Cell Preparation. After perfusing the mice with ice-cold
DPBS, the brains were removed and processed into single-cell suspensions
for mass cytometry staining, or FACS using the GentleMacs Dissociator and
Neural Tissue dissociation Kit P (Miltenyi Biotech) according to manufac-
turer’s instructions. The tumor-containing hemispheres were cut into small
pieces and placed into a GentleMacs C-tube (Miltenyi Biotech) with 1,900 μL
of Buffer X. When all brains were harvested, 50 μL of enzyme P was added,
and GentleMacs program Brain_1 was run two times followed by incubation
at 37 °C for 15 min. After running GentleMacs program Brain_2 two times,
30 μL of enzyme A solution (20 μL of Buffer Y + 10 μL of Enzyme A) was
added, followed by a second incubation at 37 °C for 10 min. After a third
round of mechanical dissociation using the Brain_3 program and 10 min of
incubation at 37 °C, single-cell suspensions were passed through a 70-μm
filter (Fisher Scientific). After a washing step, myelin was removed using
myelin removal beads (Miltenyi Biotec), and red blood cells (RBC) were lysed
during 2 min of incubation with Mouse RBC lysis buffer (Boston Bio-
products). The final single-cell suspensions were washed and stained for
FACS sorting or mass cytometry.
Mouse Splenocyte and BM Isolation. After perfusing the mice with ice-cold
PBS, the spleens and BM were removed for preparation of single-cell sus-
pensions for mass cytometry staining. Tominimize differences due to enzyme
use or other aspects of the digestion protocol, isolation of splenocytes was
performed following the same protocol as used for the single-cell preparation
of mouse brains. For the isolation of BM, the lower limbs were removed and
cleaned from all surrounding tissue, followed by a cleaning step in 70% eth-
anol. After flushing the bones with HBSS, cells were passed through a 70-μm
filter (Fisher Scientific), and incubated with the Neural Tissue Dissociation Kit
P (Miltenyi Biotech) enzymes according to the protocol for isolation of
splenocytes and brain-derived single cells, but without further mechanical
dissociation. RBC were lysed during 2 min of incubation with mouse RBC lysis
buffer (Boston Bioproducts). Due to low yield of splenocytes in mouse MGL1
and MGL6, we excluded the spleen data of these mice from further analysis.
Live/Death Staining and Barcoding. Single-cell suspensions were washed in
RPMI (no FCS) and incubated with Cisplatin (5 μM; Fluidigm) for 5 min at
37 °C, followed by a second wash with RPMI 10% FCS to quench the
Cisplatin. To ensure homogenous staining, up to 3 × 106 cells per sample
were barcoded as previously described (75) using a 20-plex Pd Barcoding
kit (Fluidigm). After fixation and permeabilization according to manu-
facturer’s directions, all samples were barcoded, assuring matching
barcodes per mouse. All brain samples were then pooled together, as
were all spleen samples and all BM samples, and frozen in FCS-dimethyl
sulfoxide (80:20) at −80 °C.
Antibodies. For each antibody used in our mass cytometry panel, the clone,
metal tag, and provider are listed in SI Appendix, Table S2. Most of the an-
tibodies we obtained from Fluidigm included metal label. Some antibodies,
however, were labeled in house according to manufacturer’s instructions us-
ing the Maxpar Antibody Labeling Kit (Fluidigm). After metal conjugation,
antibody concentrations were determined using nanodrop measurements
and diluted to appropriate concentrations. Antibodies used in this study were
titrated for optimal concentrations, and epitope availability was tested after
samples were treated with enzymes (76).
Antibody Staining. Pooled cells were thawed, washed with Cell Staining
Buffer (CSB; Fluidigm), and incubated with FcR blocking reagent (FcBlock
Trustain fcX; Biolegend) for 10 min at RT. Next, cells were incubated with a
mixture of metal-conjugated antibodies against surface markers at a con-
centration of 20 × 106 cells per mL for 30 min at RT. Following two washing
steps with CSB, cells were fixed with Fix-1 buffer (Fluidigm) for 45 min and
permeabilized by washing with permeabilization buffer (Fluidigm) for
45 min. Then, cells were incubated with antibodies against the intracellular
markers FoxP3, T-bet, CTLA-4, and Ki-67 for 30 min at RT. After two washing
steps with CSB, cells were then incubated overnight with 191/193Ir DNA
intercalator (1:4,000) diluted in Fix-1 buffer. The next day, cells were washed
once with PBS and two times with H2O before measurement.










































Mass Cytometry Data Acquisition. After washing in H2O, samples were diluted
in 0.1× EQ Four Element Calibration Beads and were acquired on a Helios
mass cytometer at a rate of 200 to 250 events per s. Samples were split into
aliquots of ∼0.8 million cells/mL to reduce sample deterioration in H2O. After
acquisition of two sample aliquots, fluidics tubing was washed with H2O,
and instrument tuning was repeated. Data were normalized during acqui-
sition, using bead normalization (77). Deconvolution of pooled samples was
performed by processing FCS files the standard single-cell debarcoding al-
gorithm for CyTOF data [single-cell debarcoding algorithm for CyTOF
data (75)].
Phenotype Specification. Debarcoded samples were then processed in FlowJo
to gate for stable flow, exclude beads, single events, and live cells. The resulting
events were then exported into FCS3.1 files and opened in Cytosplore (47) with
an arcsinh (x/5) transformation, and HSNE was computed based on CD3, CD4,
CD5, CD8, CD11b, CD11c, CD16/32, CD36, CD44, CD45, CD49d, CD54, F4/80,
GFP, Ki67, Ly-6C, Ly-6G.C, and TCRb. We used the standard recommended
parameter settings for the hierarchical construction: random walks for land-
mark selection, n = 100; Random walk length, L = 15; random walks for in-
fluence computation, n = 15. We first overclustered the embedding at the
overview level and merged clusters in a supervised manner. Decisions were
made based on (near-)identical expression of phenotyping markers and visual
inspection of the accompanying heatmap. We then proceeded to explore
successive HSNE levels of each of the overview-level clusters until we could not
find further fragmentation into clearly recognizable subpopulations. In each
new embedding, we also started by overclustering to later merge identical
clusters based on the integrated descriptive marker statistics and heatmap
visualization. The resulting cell clusters were exported as FCS3.1 files, as well
as the HSNE maps color-coded for sample, cluster, and all markers. Marker
expression profiles per cell cluster were visualized in heatmaps based on
relative Arcsinh (x/5) values using the ggplot2 package in R. Frequencies
per cell clusters were extracted using FlowJo, and statistical differences
between groups were investigated using nonparametric means compari-
son methods in SPSS.
Statistical Analysis. For the reanalysis of microarray data obtained from
Gravendeel et al. (35), the dataset was downloaded from the publicly acces-
sible data platform R2. Data were log2-transformed, and patients with grade I
glioma or a grade II or III histological diagnosis of oligo-astrocytoma were
excluded from analysis, resulting in an analysis cohort consisting of n = 21
patients with grade II, n = 60 patients with grade III, and n = 159 patients with
grade IV glioma, and n = 8 control tissue samples. Selected glycosylation re-
lated genes (SI Appendix, Table S1) were filtered and visualized in a heatmap.
Comparisons of optical density (OD) values or gene expression data between
the different glioma WHO grades were tested using a one-way ANOVA with
post hoc analysis (Tukey’s multiple comparisons test). Overall survival was
displayed in Kaplan−Meier curves. Differences in cell abundance of clusters
between mice with a WT or MGL-Lhi tumor were tested using a one-way
ANOVA with post hoc analysis. Correlations among the resulting cell clus-
ters were calculated using Spearman correlation coefficients. To ensure robust
measurements and avoid the influence of outliers, we only considered for
further analysis Spearman Correlation coefficients that remained significant
(P < 0.05) after 10 sequential iterations in which one sample was artificially
removed from the dataset. Robust correlations were ranked and visualized as
a circular network using Gephi (78), with nodes representing immune cell
types, size-coded for mean frequency for that cell type in either WT tumor-
injected mice or Cosmc knockout (KO) tumor-injected mice. Nodes were color-
coded for degree, representing the number of correlations with other cell
types. Edges in the network represent correlation coefficients, filtered for
significant correlations. Populations and their nearest neighbors were high-
lighted in orange and red.
Data Availability. The CyTOF dataset reported in this paper is publicly available
via Cytobank, https://community.cytobank.org/cytobank/experiments# (no.
86623 “Dusoswa et al. Glioblastomas exploit O-glycosylation – PNAS”).
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